Can infliximab serve as a new therapy for neuropsychiatric symptoms?

Autor: Rahmati-Dehkordi F; Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.; Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.; Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Birang N; Department of Physical Medicine and Rehabilitation, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran., Jalalian MN; Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Tamtaji Z; Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran., Dadgostar E; Behavioral Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.; Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran., Aschner M; Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA., Shafiee Ardestani M; Department of Radio Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran., Jafarpour H; Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran., Mirzaei H; Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. h.mirzaei2002@gmail.com., Nabavizadeh F; Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Nabavizadeh@tums.ac.ir.; Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Nabavizadeh@tums.ac.ir., Tamtaji OR; Electrophysiology Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. tamtaji.or@gmail.com.; Department of Physiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. tamtaji.or@gmail.com.
Jazyk: angličtina
Zdroj: Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2024 Sep 03. Date of Electronic Publication: 2024 Sep 03.
DOI: 10.1007/s00210-024-03397-w
Abstrakt: Neuropsychiatric disorders present a global challenge to public health. Mechanisms associated with neuropsychiatric disorders etiology include apoptosis, oxidative stress, and neuroinflammation. Tumor necrosis factor alpha, an inflammatory cytokine, mediates pathophysiology of neuropsychiatric disorders. Therefore, its inhibition by infliximab might afford a valuable target for intervention. Infliximab is commonly used to treat inflammatory diseases, including ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Recently, it has been shown that infliximab improves cognitive dysfunction, depression, anxiety, and life quality. Here, we review contemporary knowledge supporting the need to further characterize infliximab as a potential treatment for neuropsychiatric disorders.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: